ClinicalTrials.gg
RecruitingNCT07883577Updated Nov 16, 2026

A Study of RO7821657 in Participants With Solid Tumors

A Phase 1 interventional study of RO7821657 in Locally Advanced or Metastatic Solid Tumors, sponsored by Hoffmann-La Roche. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Updated Nov 16, 2026Now RecruitingFirst sites in Denmark and United Kingdom+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
405
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to characterize the safety and tolerability of RO7821657, describe its pharmacokinetics (PK), and evaluate pharmacodynamic and biomarker effects to support selection of the recommended Phase 2 dose(s) (RP2D[s])

The study consists of two parts, namely Part 1 and Part 2:

Part 1: Evaluation of RO7821657 as monotherapy in participants with microsatellite-stable (MSS) colorectal cancer (CRC).

Part 2: Evaluation of RO7821657 as monotherapy in participants with non-squamous non-small cell lung cancer (NSCLC)

02

Conditions studied

  • Locally Advanced or Metastatic Solid Tumors
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • estimated by the Investigator to be ≥12 weeks.
  • (ECOG) Performance Status (PS) 0-1.
  • Presence of according to (RECIST) v1.1; previously irradiated lesions are considered measurable if progression has been demonstrated in such lesions after the irradiation.
  • Availability of or tissue obtained from a fresh biopsy at screening if formalin-fixed paraffin-embedded [FFPE]-preserved archival tissue is not available. The archival tumor tissue should come from a core biopsy, a punch biopsy, an excisional biopsy, or a surgical specimen. Lymph node biopsy, bone biopsy (unless from soft tissue), or fine needle aspiration are unacceptable for submission. Lesions that are intended to be biopsied should not be counted as target lesions.
  • Adequate cardiovascular function:

(NYHA) Heart Failure Class ≤ 1.

  • Agreement to adhere to the requirements.

Exclusion criteria

Exclusion Criteria:

  • Participants with active Central Nervous System (CNS) .
  • Any unresolved toxicities from prior therapy, i.e., radiotherapy, chemotherapy, targeted or therapy or surgical procedure, greater than Grade 1 at the time of starting study treatment, except for alopecia and Grade 2 neuropathy.

    a) Stable endocrine AEs managed with hormone replacement are permitted, including hypothyroidism on stable thyroid hormone replacement.

  • History of interstitial pulmonary disease, drug-induced pneumonitis, or evidence of active pneumonitis on screening computed tomography (CT) scan.
  • Participants with pulmonary miliary metastatic pattern (innumerable small lesions) or pulmonary lymphangitic carcinomatosis.
  • Active disease that has required systemic treatment (except replacement treatment) within the last 2 years or any disease requiring therapy while on study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
405 participants (estimated)

Study arms

  • Experimental
    Part 1A: Dose Escalation

    Participants with MSS CRC will receive multiple doses of RO7821657 in single and multiple participant cohorts.

    Drug: RO7821657

  • Experimental
    Part 1B: Backfill Cohorts

    Participants with MSS CRC will receive RO7821657 at dosing regimen selected based on data from Part 1A.

    Drug: RO7821657

  • Experimental
    Part 1C: Dose Expansion/Optimization

    Participants with MSS CRC will receive RO7821657 at dosing regimens selected based on data from Parts 1A and 1B.

    Drug: RO7821657

  • Experimental
    Part 2A: Abbreviated Dose Escalation

    Participants with non-squamous NSCLC will receive multiple doses of RO7821657 in multiple participant cohorts.

    Drug: RO7821657

  • Experimental
    Part 2B: Dose Expansion/Optimization

    Participants with non-squamous NSCLC will receive RO7821657 at dosing regimen selected based on data from Part 2A.

    Drug: RO7821657

Interventions

  • DrugRO7821657

    Participants will receive RO7821657 as per the schedule described in the protocol.

06

What researchers measure

Primary outcomes

  1. Part 1: Incidence and Severity of Adverse Events (AEs)

    AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any events of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded based on the American Society for Transplantation and Cellular Therapy (ASTCT) criteria

    Time frame: Up to approximately 27 months

  2. Part 2: Incidence and Severity of Adverse Events (AEs)

    AEs will be graded according to NCI CTCAE v5.0. Any events of CRS and ICANS will be graded based on the ASTCT criteria

    Time frame: Up to approximately 27 months

  3. Part 1A: Nature and Frequency of Dose-limiting Toxicities (DLTs)

    Time frame: From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days)

  4. Part 2A: Nature and Frequency of DLTs

    Time frame: From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days)

  5. Parts 1A and 1B: Recommended Phase 2 Dose (RP2D) Range of RO7821657

    Time frame: Up to approximately 27 months

  6. Part 2A: RP2D Range of RO7821657

    Time frame: Up to approximately 27 months

Secondary outcomes

  1. Parts 1 and 2: Serum Concentration of RO7821657

    Time frame: Up to approximately 27 months

  2. Parts 1 and 2: Objective Response Rate (ORR)

    Time frame: Up to approximately 27 months

  3. Parts 1 and 2: Disease Control Rate (DCR)

    Time frame: Up to approximately 27 months

  4. Parts 1 and 2: Duration of Response (DoR)

    Time frame: Up to approximately 27 months

  5. Parts 1 and 2: Progression-free Survival (PFS)

    Time frame: Up to approximately 27 months

  6. Parts 1 and 2: PFS Rate

    Time frame: At 6 months

  7. Parts 1 and 2: Overall Survival (OS) Rate

    Time frame: At 6 months

  8. Parts 1 and 2: Correlation of Baseline Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Tumor Expression With Clinical Activity

    Time frame: Up to approximately 27 months

  9. Part 1B: Cluster of Differentiation 8 (CD8) Expression in Tumor Tissue

    Time frame: Up to approximately 27 months

  10. Parts 1C and 2B: Percentage of Participants With Presence, Frequency, Severity and Interference of Symptomatic Treatment Toxicities as Assessed by NCI Patient-reported Outcomes (PRO)-CTCAE

    Time frame: Up to approximately 27 months

  11. Parts 1C and 2B: Change From Baseline in Symptomatic Treatment Toxicities as Assessed by NCI PRO-CTCAE

    Time frame: Up to approximately 27 months

  12. Parts 1C and 2B: Percentage of Participants Troubled by Treatment Symptoms, as Assessed by Single Item European Organisation for Research and Treatment of Cancer Item Library 46 (EORTC IL46)

    Time frame: Up to approximately 27 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2026 (actual). Primary completion is estimated for May 2030, 42 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Oct 20, 2026
StartActual
Nov 10, 2026was Oct 2026
Primary completionEst.
May 31, 2030
CompletionEst.
May 31, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
2 sites added — first sites in Denmark and United Kingdom
Show 2 added (1 Denmark, 1 United Kingdom)
  • Rigshospitalet · København Ø, Denmark
  • Royal Marsden Sutton · Sutton, United Kingdom
Nov 16, 2026
Start date
Oct 26, 2026→Nov 10, 2026 (actual)
Nov 16, 2026
Registered
First appeared on the registry
Oct 20, 2026
Show all 2 updates
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    2 sites added — first sites in Denmark and United Kingdom
    Show 2 added (1 Denmark, 1 United Kingdom)
    • Rigshospitalet · København Ø, Denmark
    • Royal Marsden Sutton · Sutton, United Kingdom
    Start date Oct 26, 2026→Nov 10, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07883577
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 20, 2026
Start date
Nov 10, 2026
Primary completion
May 31, 2030 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Reference Study ID Number: BP46447 https://forpatients.roche.com/
Contact
global-roche-genentech-trials@gene.com
888-662-6728
Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion